Innovative Molecules doses first patient in Phase 2a trial
The study evaluates the oral helicase-primase inhibitor's safety, antiviral activity, pharmacokinetics and efficacy in recurrent genital herpes.
See the latest news and media coverage for Innovative Molecules. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing antiviral treatments for herpes-related diseases
innovativemolecules.comLast updated
In short: Innovative Molecules advanced oral adibelivir into Phase 2a and licensed parenteral rights to Alfasigma.
The study evaluates the oral helicase-primase inhibitor's safety, antiviral activity, pharmacokinetics and efficacy in recurrent genital herpes.
The oral HSV helicase primase inhibitor advances to the Phase 2a efficacy part of the IM-202 trial in patients with genital herpes.
Alfasigma also invests in Innovative Molecules and pays up to €125 million in upfront and milestones; Innovative Molecules keeps the oral formulation.
The round is led by LSP and the funds will advance the preclinical herpes drug candidate IM-250 into a Phase 2 proof-of-concept study.
MUNICH, June 25, 2026 /PRNewswire/ -- Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that...
MUNICH, June 16, 2026 /PRNewswire/ -- Innovative Molecules GmbH ("IM"), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its ...
BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology...
Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease PR Newswire BOLOGNA, Italy and MUNICH, Jan...
Track Innovative Molecules and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.